Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Aptevo Therapeutics Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +2 vs. Q2 2024
- Shares held
- 1.28M
- −679.5K (−34.6%) vs. Q2 2024
- Total value
- $231.1K
- −$367.7K (−61.4%) vs. Q2 2024
- New holders
- 7
- 4 more added
- Sold out
- 5
- 3 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting APVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $224.3K |
| Q1 2026 | 9 | $229.7K |
| Q4 2025 | 11 | $191.4K |
| Q3 2025 | 12 | $717.1K |
| Q2 2025 | 7 | $45.9K |
| Q1 2025 | 8 | $22.8K |
| Q4 2024 | 13 | $208.7K |
| Q3 2024 | 19 | $231.1K |
| Q2 2024 | 18 | $599.1K |
| Q1 2024 | 10 | $12.4K |
| Q4 2023 | 29 | $349.7K |
| Q3 2023 | 26 | $1.13M |
| Q2 2023 | 23 | $1.36M |
| Q1 2023 | 24 | $1.82M |
| Q4 2022 | 27 | $2.27M |
| Q3 2022 | 27 | $2.63M |
| Q2 2022 | 27 | $2.85M |
| Q1 2022 | 24 | $4.76M |
| Q4 2021 | 23 | $5.99M |
| Q3 2021 | 26 | $42.1M |
| Q2 2021 | 29 | $65.5M |
| Q1 2021 | 34 | $89.7M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Aptevo Therapeutics Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Hudson Bay Capital Management LP | 935,552 | $168.2K | 0.00% | +435,552+87.1% | Added |
| Citadel Advisors LLC | 111,632 | $20.1K | 0.00% | +111,632 | New |
| Virtu Financial LLC | 41,967 | $8.00K | 0.00% | +24,572+141.3% | Added |
| Geode Capital Management, LLC | 43,684 | $7.85K | 0.00% | +24,299+125.3% | Added |
| Renaissance Technologies LLC | 36,575 | $6.58K | 0.00% | +36,575 | New |
| Two Sigma Securities, LLC | 28,020 | $5.04K | 0.00% | +28,020 | New |
| HRT Financial LP | 28,116 | $5.00K | 0.00% | −2,444−8.0% | Reduced |
| Tower Research Capital LLC (TRC) | 25,069 | $4.51K | 0.00% | +17,331+224.0% | Added |
| Jane Street Group, LLC | 17,218 | $3.10K | 0.00% | +17,218 | New |
| Two Sigma Investments, LP | 14,195 | $2.55K | 0.00% | +14,195 | New |
| BlackRock, Inc. | 888 | $160 | 0.00% | +888 | New |
| Morgan Stanley | 194 | $35 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 77 | $14 | 0.00% | −83−51.9% | Reduced |
| JPMorgan Chase & Co | 43 | $8 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 45 | $8 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 33 | $6 | 0.00% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 3 | $1 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 1 | $0 | 0.00% | −115,909−100.0% | Reduced |
| Truvestments Capital LLC | 2 | $0 | 0.00% | +2 | New |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −749,234−100.0% | Sold out |
| Sabby Management, LLC | 0 | $0 | 0.00% | −501,499−100.0% | Sold out |
| Baader Bank INC | 0 | $0 | 0.00% | −20,152−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Fifth Third Bancorp | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |